SCHEMBL7225939

SCHEMBL7225939

Cc1ccn2c(-c3cccc(-c4ccccc4C=NO)c3)cnc2n1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 17/20 0.62
GABRB3 P28472 17/20 0.62
GABRA1 P14867 16/20 0.62
GABRA3 P34903 15/20 0.62
GABRA5 P31644 10/20 0.62
GABRA2 P47869 5/20 0.62
BACE1 P56817 1/20 0.36
FLT3 P36888 1/20 0.35
DYRK3 O43781 1/20 0.34
CCNT1 O60563 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CDK9 P50750 1/20 0.34
CDK5 Q00535 1/20 0.34
DYRK1A Q13627 1/20 0.34
CDK5R1 Q15078 1/20 0.34
DYRK2 Q92630 1/20 0.34
DYRK1B Q9Y463 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7225937 1.00 GABRG2 (0.62) GABRG2GABRB3GABRA1GABRA3GABRA5
SCHEMBL7224559 0.80 GABRA1 (0.70) GABRG2GABRB3GABRA1GABRA3GABRA5
SCHEMBL7224413 0.78 GABRA1 (0.67) GABRG2GABRB3GABRA1GABRA3GABRA5
SCHEMBL2659147 0.77 GABRA1 (1.00) GABRG2GABRB3GABRA1GABRA3GABRA5
SCHEMBL7231276 0.77 GABRA1 (0.66) GABRG2GABRB3GABRA1GABRA3GABRA5
SCHEMBL7234152 0.75 GABRA1 (0.60) GABRG2GABRB3GABRA1GABRA3GABRA5
SCHEMBL7226062 0.74 GABRG2 (0.62) GABRG2GABRB3GABRA1GABRA3GABRA5
SCHEMBL7231057 0.74 GABRA1 (0.68) GABRG2GABRB3GABRA1GABRA3GABRA5
SCHEMBL7231054 0.74 GABRA1 (0.68) GABRG2GABRB3GABRA1GABRA3GABRA5
SCHEMBL7232228 0.74 GABRG2 (0.61) GABRG2GABRB3GABRA1GABRA3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642229-B2 Treatment of adverse neurological conditions MERCK SHARP & DOHME LTD. 2003-11-04 US claimed
US-6642229-B2 Treatment of adverse neurological conditions MERCK SHARP & DOHME LTD. 2003-11-04 US disclosed